Elisabeth Baux

Dr. Elisabeth Baux

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
NSNGUALA STEVE
NGUALA STEVE
EBElisabeth Baux
Elisabeth Baux
SPSolène Patrat-Delon
Solène Patrat-Delon
FSFlorian Saunier
Florian Saunier
JSJulien Schemoul
Julien Schemoul
ARAlice Raffetin
Alice Raffetin
Background: Most European and American countries recently updated their guidelines on Lyme borreliosis (LB). The aim of this study was to provide a comparative overview of existing guidelines on the treatment of LB in Europe and America and to assess the methodological quality of their elaboration. Methods: A systematic search was carried out in MEDLINE, Google Scholar, and the national databases of scientific societies from 2014 to 2020. Quality was assessed by two independent reviewers using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool. Results: Twelve guidelines were included. The scores for the AGREE II domains (median ± IQR) were: overall assessment 100 ± 22, scope and purpose 85 ± 46, stakeholder involvement 88 ± 48, rigour of development 67 ± 35, clarity of presentation 81 ± 36, applicability 73 ± 52 and editorial independence 79% ± 54%. Cohen’s weighted kappa showed a high agreement (K = 0.90, 95%CI 0.84–0.96). Guidelines were quite homogeneous regarding the recommended molecules (mostly doxycycline in the first intention and ceftriaxone in the second intention), their duration (10 to 28 days), and their dosage. The differences were due to the lack of well-conducted comparative trials. The International Lyme and Associated Diseases Society (ILADS) guidelines were the only ones to suggest longer antibiotics based on an expert consensus. Conclusion: European and American guidelines for the treatment of LB were quite homogeneous but based on moderate- to low-evidence studies. Well-conducted comparative trials are needed to assess the best molecules, the optimal duration and the most effective doses.

12 March 2022 in eClinicalMedicine
Verified
Journal Article
Open access
SDSophie Demotier
Sophie Demotier
ALAnne Limelette
Anne Limelette
ACAlexandre Charmillon
Alexandre Charmillon
EBElisabeth Baux
Elisabeth Baux
XPXavier Parent
Xavier Parent
MHMaxime Hentzien
Maxime Hentzien
Amoxicillin crystalluria (AC), potentially responsible for acute kidney injury (AKI), is reported more and more frequently in patients treated with high doses of intravenous amoxicillin (HDIVA). The main objective of this study was to evaluate AC incidence in these patients. The secondary objectives were to identify factors associated with AC and to evaluate its impact on the risk of AKI. This multicentre, observational, cohort study was conducted between Mar 18, 2014 and Aug 16, 2019 in Dijon, Nancy, and Reims University Hospitals as well as Châlon-sur-Saône, Charleville-Mézières, and Troyes general hospitals in France. Adult patients (≥18 years) treated with HDIVA and having been tested for AC at least once during treatment were included. Clinical, biological, and therapeutic characteristics of the patients were collected. A univariable mixed logistic regression model assessed the factors associated with AC. A multivariable Cox model with AC as a time-dependent variable assessed the prognostic factors for AKI. ClinicalTrials.gov number: NCT02853292. Of the 112 included patients, 27 (24.1%, 95% CI [16.2-32.0]) developed at least one episode of AC within a mean of 5.1 days. The factors associated with its occurrence were the concomitant use of angiotensin converting enzyme (ACE) inhibitors (OR=4.6, 95% CI [2.2-9.3], p<0.0001) and the decrease of urinary pH (OR=2.1 for one pH point decrease, 95% CI [1.2-3.7], p=0.009). 20 patients (17.9%) presented with AKI, within a mean time of 10.9 days. The main factor associated with the occurrence of AKI was the occurrence of AC (aHR=7.4, 95% CI [2.5-22.2], p=0.0003). AC occurred in a quarter of patients treated with HDIVA and was highly prognostic of AKI. None.

26 November 2025 in Infectious Diseases Now
Verified
Journal Article
Closed access
ARAlice Raffetin
Alice Raffetin
FRF. Roblot
F. Roblot
LCLENORMAND Cédric
LENORMAND Cédric
YHY. Hansmann
Y. Hansmann
EBElisabeth Baux
Elisabeth Baux
KBK. Bouiller
K. Bouiller

17 April 2025 in Infection
Verified
Journal Article
Closed access
PDF file
ARAlice Raffetin
Alice Raffetin
AHAnna J Henningsson
Anna J Henningsson
KOKatharina Ornstein
Katharina Ornstein
PAPauline Arias
Pauline Arias
VFVolker Fingerle
Volker Fingerle
TDthe ESGBOR the ESCMID study group for Tick-Borne Diseases
the ESGBOR the ESCMID study group for Tick-Borne Diseases

6 November 2024 in Vector-Borne and Zoonotic Diseases
Verified
Journal Article
Open access
CNCharles Nuttens
Charles Nuttens
SDStéphanie Duret
Stéphanie Duret
ABAntoine Bessou
Antoine Bessou
EBElisabeth Baux
Elisabeth Baux
JFJean-François Faucher
Jean-François Faucher
JSJames H. Stark
James H. Stark
Background: Lyme borreliosis (LB) remains a public health concern in France despite improved patient management and medical care. Stay-at-home restrictions during the COVID-19 pandemic, which affected participation in outdoor recreational activities and disrupted access to health care services, may have impacted the risk of developing LB. Methods: We analyzed data from two general practitioner networks in France (Sentinel Network and an electronic medical records database [EMR]) and the national hospital discharge database to describe LB epidemiology in 2020–2021 and compare it to previous years. Google Trends’ search volume was used to evaluate the association between the population’s interest in LB and the evolving epidemiology. Results: Annual LB incidence rates in primary care decreased from 104 cases/100,000 population in 2018 to 71/100,000 in 2021 and from 82/100,000 to 60/100,000 according to Sentinel Network and EMR, respectively. Google Trends’ search volume for “Lyme” followed a similar trend, one year earlier. Annual hospitalizations were stable from 2012–2019 (1.6/100,000 on average) and declined to 1.3/100,000 in 2020 and 1.1/100,000 in 2021. This decline was observed primarily in adults ( e.g., 3.4/100,000 in 2017–2019 to 1.8/100,000 in 2020–2021 for 70–79 years of age). Changes in regional incidence rates in primary care from 2017–2019 to 2020–2021 ranged from −75% to 208%. Hospitalizations decreased in all regions except in Bretagne. Conclusions: The estimated LB incidence decreased in 2020 and 2021 compared with previous years but this change may not be related to COVID-19. The incidence decrease observed in primary care could result from reduced population interest in LB, leading to lower care-seeking behavior. The decrease in LB hospitalizations may be explained by changes in clinical practice. Surveillance systems are critical to understand the evolution of LB epidemiology. However, external factors impacting incidence estimates should be considered.

28 November 2025 in Infectious Diseases Now
Verified
Journal Article
Closed access
EBElisabeth Baux
Elisabeth Baux
YHYves Hansmann
Yves Hansmann
CTChristine Tranchant
Christine Tranchant
FRFrance Roblot
France Roblot
PAPauline Arias
Pauline Arias
ARAlice Raffetin
Alice Raffetin